Anacor Pharmaceuticals, Inc. (ANAC)

99.20
NASDAQ
Prev Close 99.20
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Anacor Pharmaceuticals Announces 2013 Fourth Quarter And Year End Financial Results Conference Call And Webcast

Anacor Pharmaceuticals Announces 2013 Fourth Quarter And Year End Financial Results Conference Call And Webcast

Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the fourth quarter and year ended December 31, 2013 on Thursday, March 13, 2014 at approximately 4:00 p.

Anacor Pharmaceuticals Announces Successful Completion Of End-of-Phase 2 Meeting With FDA For The Treatment Of Mild-to-Moderate Atopic Dermatitis With AN2728

Anacor Pharmaceuticals Announces Successful Completion Of End-of-Phase 2 Meeting With FDA For The Treatment Of Mild-to-Moderate Atopic Dermatitis With AN2728

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has successfully completed an End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) for the topical treatment of mild-to-moderate...

Anacor Pharmaceuticals To Present At The Cowen & Company 34th Annual Health Care Conference

Anacor Pharmaceuticals To Present At The Cowen & Company 34th Annual Health Care Conference

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Geoff Parker, the company’s Chief Financial Officer, will provide a company overview at the Cowen & Company 34th Annual Health Care Conference on Monday, ...

Anacor Pharmaceuticals Announces Publication Of Article Describing Boron-Containing Compounds And Their Relevance To Dermatology

Anacor Pharmaceuticals Announces Publication Of Article Describing Boron-Containing Compounds And Their Relevance To Dermatology

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that a peer-reviewed article describing the recent progress of boron-based compounds in medicine and the properties of these compounds that support their development...

Today Anacor Pharmaceuticals (ANAC) Hits New Lifetime High

Today Anacor Pharmaceuticals (ANAC) Hits New Lifetime High

Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a new lifetime high candidate

Anacor Pharmaceuticals Stock Sees Short Interest Move 13.2% Higher

Anacor Pharmaceuticals Stock Sees Short Interest Move 13.2% Higher

The most recent short interest data has been released by the NASDAQ for the 12/31/2013 settlement date, which shows a 377,261 share increase in total short interest for Anacor Pharmaceuticals Inc , to 3,239,968, an increase of 13.18% since 12/13/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week of ANAC August 16th Options Trading

First Week of ANAC August 16th Options Trading

Investors in Anacor Pharmaceuticals Inc saw new options begin trading this week, for the August 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 215 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Anacor Pharmaceuticals Is Not for Everyone

Anacor Pharmaceuticals Is Not for Everyone

This stock isn't for widows and orphans. It's for an aggressive portfolio.

Anacor Pharmaceuticals (ANAC) Hits New Lifetime High Today

Anacor Pharmaceuticals (ANAC) Hits New Lifetime High Today

Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a new lifetime high candidate

Short Interest Makes 10.5% Move For ANAC

Short Interest Makes 10.5% Move For ANAC

The most recent short interest data has been released by the NASDAQ for the 11/29/2013 settlement date, which shows a 250,583 share increase in total short interest for Anacor Pharmaceuticals Inc , to 2,636,306, an increase of 10.50% since 11/15/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Top Insider Trades: AGYS, ANAC, P, GMZ

Top Insider Trades: AGYS, ANAC, P, GMZ

The top 10 open-market insider purchases and sales filed at the SEC Wednesday.

Anacor Pharmaceuticals To Present At The 25th Annual Piper Jaffray Healthcare Conference

Anacor Pharmaceuticals To Present At The 25th Annual Piper Jaffray Healthcare Conference

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Geoff Parker, the company’s Chief Financial Officer, will provide a company overview at the 25 th Annual Piper Jaffray Healthcare Conference on Wednesday,...

2014 FDA Drug Approval Decision Calendar

2014 FDA Drug Approval Decision Calendar

Here's a list of 34 FDA drug approval decisions and scheduled advisory panels from December 31 through October 2014.

4 Stocks Rising on Big Volume

4 Stocks Rising on Big Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Anacor Pharmaceuticals Announces Positive Preliminary Results From AN2728 MUSE Study In Pediatric And Adolescent Patients With Atopic Dermatitis

Anacor Pharmaceuticals Announces Positive Preliminary Results From AN2728 MUSE Study In Pediatric And Adolescent Patients With Atopic Dermatitis

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive results from its maximal use systemic exposure (MUSE) study of its boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728, in pediatric and adolescent...

Anacor Pharmaceuticals Reports Third Quarter 2013 Financial Results

Anacor Pharmaceuticals Reports Third Quarter 2013 Financial Results

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced its financial results for the third quarter ended September 30, 2013.

Anacor Pharmaceuticals Announces Third Quarter 2013 Financial Results Conference Call And Webcast

Anacor Pharmaceuticals Announces Third Quarter 2013 Financial Results Conference Call And Webcast

Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the third quarter ended September 30, 2013, on Thursday, November 7, 2013 at approximately 4:00 p.

Anacor Pharmaceuticals Announces Settlement Agreement With Valeant Pharmaceuticals

Anacor Pharmaceuticals Announces Settlement Agreement With Valeant Pharmaceuticals

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that it has entered into a settlement agreement with Valeant Pharmaceuticals International, Inc.

First Week Of ANAC December 21st Options Trading

First Week Of ANAC December 21st Options Trading

Investors in Anacor Pharmaceuticals Inc saw new options become available this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ANAC options chain for the new December 21st contracts and identified one put and one call contract of particular interest.

New Lifetime High Reached: Anacor Pharmaceuticals (ANAC)

New Lifetime High Reached: Anacor Pharmaceuticals (ANAC)

Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a new lifetime high candidate

Anacor Pharmaceuticals Awarded U.S. Government Funding To Discover New Classes Of Systemic Antibiotics

Anacor Pharmaceuticals Awarded U.S. Government Funding To Discover New Classes Of Systemic Antibiotics

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced it has entered into a research agreement with the United States Department of Defense, Defense Threat Reduction Agency (DTRA) to design and discover new classes of...

Anacor Pharmaceuticals Announces Favorable Ruling In Its Arbitration With Valeant Pharmaceuticals

Anacor Pharmaceuticals Announces Favorable Ruling In Its Arbitration With Valeant Pharmaceuticals

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that the arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc.

Anacor Pharmaceuticals Announces FDA Acceptance Of Tavaborole NDA For Filing

Anacor Pharmaceuticals Announces FDA Acceptance Of Tavaborole NDA For Filing

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its New Drug Application (NDA) for tavaborole, its drug candidate for the topical treatment of onychomycosis, has been accepted by the U.

5 Stocks Rising on Big Volume

5 Stocks Rising on Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Not a Good Sign

The technical picture demands caution.

Anacor: Overvalued On Weak Drug Pipeline

Anacor: Overvalued On Weak Drug Pipeline

Anacor's toenail fungus and dermatitis drugs aren't as effective as competing treatments.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

Top Insider Trades: S TSRA PMCS ANAC

Top Insider Trades: S TSRA PMCS ANAC

The top 10 open-market insider purchases and sales filed at the SEC Tuesday.

Anacor Pharmaceuticals To Present At Upcoming Investor Conferences

Anacor Pharmaceuticals To Present At Upcoming Investor Conferences

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the company’s Chief Executive Officer, will provide a company overview at the following investor conferences: Wedbush...